4MO Role of ctDNA tumor fraction to select immunotherapy based regimens in advanced non-small cell lung cancer
The emergence of immune checkpoint blockers (ICBs) transformed treatment for advanced non-small cell lung cancer (aNSCLC), but determining when to combine them with chemotherapy remains challenging. Biomarkers like PD-L1 expression and Tumor Mutation Burden guide treatment decisions, but are imperfect, and direct comparison data between ICB monotherapy and chemo-immunotherapy are lacking. Imaging-based tumor burden and liquid biopsy (LBx), particularly circulating tumor DNA (ctDNA) levels, offer promise in this regard.
Authors
- Lincoln W. Pasquina (ORCID: https://orcid.org/0009-0009-5461-9777)
- Wael Zrafi (ORCID: https://orcid.org/0000-0003-4289-6821)
- Kristi Beshiri (ORCID: https://orcid.org/0000-0001-5776-9070)
- Russell W. Madison (ORCID: https://orcid.org/0000-0002-7838-2526)
- D. Planchard
- F. Barlesi
- A. Italiano
- B. Besse
- F.G. Dall'Olio
- C.A. Garcia
- Damien Vasseur (ORCID: https://orcid.org/0000-0001-8787-1498)
- Arianna Marinello (ORCID: https://orcid.org/0000-0003-3966-1984)
- L. Lacroix
- Étienne Rouleau (ORCID: https://orcid.org/0000-0002-9046-257X)
Institutions
- Biogen (United States) (US)
- Institut Gustave Roussy (FR)
- Institut Bergonié (FR)
- Foundation Medicine (United States)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100888
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00